BCM
IBB icon

Bluefin Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

Bluefin Capital Management’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-56,100
Closed -$274K – 796
2014
Q3 		$274K Buy
+56,100
New +$4.92M 0.02% 518

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Bluefin Capital Management's IBB Position: Q1 2017 in Review

Bluefin Capital Management sold out of iShares Biotechnology ETF (IBB) in Q1 2017, closing a stake of 4,908 shares — an estimated $435K sold.

Bluefin Capital Management first reported a position in IBB in Q2 2013 and held it in 11 quarters. The position peaked at $900K in Q2 2013. 521 funds tracked by Wall St. Rank hold IBB as of Q1 2017.

  • Bluefin Capital Management reported no remaining iShares Biotechnology ETF position as of Q1 2017 after selling out during the quarter.
  • Bluefin Capital Management sold 4,908 iShares Biotechnology ETF shares in Q1 2017, an estimated $435K.
  • Bluefin Capital Management first reported a position in iShares Biotechnology ETF in Q2 2013 and held it in 11 quarters.
  • Bluefin Capital Management's iShares Biotechnology ETF position peaked at $900K in Q2 2013.
  • 521 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2017.

Based on Bluefin Capital Management's 13F filing for Q1 2017, filed 15 May 2017.